EASL 2019 Vienna : Assembly Biosciences, Inc.

Event Details

EASL 2019 Vienna

Apr 15, 2019

Supporting Materials

Assembly Bio EASL 2019 Review 1.4 MB

EASL 2019, Vienna, "Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers" 370 KB

EASL 2019, Vienna, “Preclinical Profile of HBV Core Protein Inhibitor, ABI-H3733, a Potent Inhibitor of cccDNA Generation in HBV Infected Cells” 1 MB

EASL 2019, Vienna, "Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough" 566.6 KB

Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with Nuc Therapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients 581.6 KB

Shareholder Tools

Search Investors